Pancreatic Cancer Research

ResearcherStony Brook UniversityActive in the last 2 years

Minsig Choi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5113520697. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 4 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 13

  1. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/ajcp/aqae038↗
  2. Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Co-author DOI 10.1038/s41416-020-0879-6↗
  3. Challenges in Ras therapeutics in pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2017.11.015↗
  4. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0298-0↗
  5. Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcin… Last author DOI 10.1101/mcs.a004424↗
  6. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives. Last author DOI 10.2147/ott.s167590↗
  7. Immune Therapy in Pancreatic Cancer: Now and the Future? First author DOI 10.2174/1574887110666150916142537↗
  8. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advan… Co-author DOI 10.1016/j.radonc.2014.08.014↗
  9. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Co-author DOI 10.2147/ott.s40705↗
  10. Is there a role for second line therapy in advanced pancreatic cancer? Co-author DOI 10.6092/1590-8577/2325↗
  11. Biomarkers for pancreatic cancer: is it ready for primetime? Co-author DOI 10.6092/1590-8577/1676↗
  12. What options are available for refractory pancreatic cancer? Co-author DOI 10.6092/1590-8577/720↗
  13. Systemic therapy of advanced pancreatic cancer: has the landscape changed? Co-author PMID 22895284↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenneth Reed Shroyer · 3 shared papers, 2019–2024 · strength 0.36
  2. Richard D. Kim · 4 shared papers, 2012–2014 · strength 0.23
  3. Scott Powers · 2 shared papers, 2019 · strength 0.22
  4. Jeffrey L. Vacirca · 2 shared papers, 2019–2020 · strength 0.18
  5. Marcela d'Alincourt Salazar · 2 shared papers, 2019–2020 · strength 0.18
  6. Mei Gao · 2 shared papers, 2019–2020 · strength 0.18
  7. Richard A. Moffitt · 2 shared papers, 2019–2020 · strength 0.18
  8. Joseph Kim · 2 shared papers, 2019–2020 · strength 0.18
  9. Emanuel F. Petricoin · 1 shared paper, 2024 · strength 0.17
  10. Andrew Eugene Hendifar · 1 shared paper, 2024 · strength 0.17
  11. Lucia Roa‐Peña · 1 shared paper, 2024 · strength 0.17
  12. Brent K. Larson · 1 shared paper, 2024 · strength 0.17
  13. Lyanne Delgado Coka · 1 shared paper, 2024 · strength 0.17
  14. Luisa F. Escobar‐Hoyos · 1 shared paper, 2024 · strength 0.17
  15. Vincent J. Picozzi · 1 shared paper, 2024 · strength 0.17
  16. Wei Jiang · 1 shared paper, 2024 · strength 0.17
  17. Lynn McCormick Matrisian · 1 shared paper, 2024 · strength 0.17
  18. Wonhee Woo · 1 shared paper, 2019 · strength 0.16
  19. Harold Bien · 1 shared paper, 2019 · strength 0.14
  20. Muhammad Wasif Saif · 2 shared papers, 2012–2014 · strength 0.12
  21. Yue Zhang · 1 shared paper, 2015 · strength 0.11
  22. Kazimierz O. Wrzeszczyński · 1 shared paper, 2019 · strength 0.08
  23. Asfar Sohail Azmi · 1 shared paper, 2014 · strength 0.07
  24. Mohammad Saif · 1 shared paper, 2013 · strength 0.05
  25. Amit Mahipal · 1 shared paper, 2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.